State Board of Pharmacy December 19, 2023

3 4 5

6

1

2

BOARD MEMBERS:

7 9 10

11

12 13 14

15 16 17

18

19

20

21

22

23

24 25 26

27 28

33 34 35

37 38 39

36

40 41 42

43 44 45

50

Theresa M. Talbott, R.Ph., Chairperson Arion R. Claggett, Acting Commissioner, Bureau of Professional and Occupational Affairs Christine Roussel, Pharm.D., BCOP, BCSCP, Vice Chairperson Eric Esterbrook, R.Ph., Secretary John R. Slagle, R.Ph. Janet Getzey Hart, R.Ph. Tyler Ritchie, Esquire, Deputy Attorney General, Office of Attorney General

BUREAU PERSONNEL:

Carole Clarke Smith, Esquire, Senior Board Counsel Ariel O'Malley, Esquire, Board Counsel Megan E. Castor, Esquire, Board Counsel Todd P. Kriner, Esquire, Board Counsel Judith Pachter Schulder, Esquire, Board Counsel Ray J. Michalowski, Esquire, Senior Board Prosecutor Nathan C. Giunta, Esquire, Board Prosecution Liaison Glenn P. Masser, Esquire, Board Prosecutor Ashley P. Murphy, Esquire, Board Prosecutor Caroline A. Bailey, Esquire, Board Prosecutor Angela L. Solomon, Esquire, Board Prosecutor Melanie Zimmerman, R.Ph., Board Administrator Marc Farrell, Esquire, Regulatory Counsel, Office of Chief Counsel, Department of State Jessica Zukoski, Senior Legal Analyst, Department of State

Michael McDonald, Policy Director, Department of

ALSO PRESENT:

State

Kevin Knipe, MSW, LSW, CCDP Diplomate, Program Manager, Professional Health Monitoring Program Chiara Huber, Pharmacy Student Grace Sesi, Executive Director, Regulatory Affairs at CVS Health/Chairperson, Michigan Board of Pharmacy Julie Droddy, Drug and Alcohol Program Manager, Professional Health Monitoring Program

State Board of Pharmacy December 19, 2023

1

2

ALSO PRESENT: (cont.)

7 8

9

10 11 12

13 14

15 16 17

18

19 20

21 22 23

24 25 26

35

46 47

45

48 49 50 Heather A. Wilson, MSW, CFRE, CAE, Executive Director of The Foundation of the Pennsylvania Medical Society, Deputy Executive Vice President of the Pennsylvania Medical Society

Tiffany Booher, MA, LPC, CAADC, CIP, CCSM, Director, Peer Assistance Monitoring Programs; Program Director, Physicians' Health Program, Pennsylvania Medical Society

Raymond Truex Jr., MD, FACS, FAANS, Medical Director, Physicians' Health Program, Pennsylvania Medical Society

Victoria Elliott, RPh, MBA, CAE, CEO, Pennsylvania Pharmacists Association

Larry Jones, Executive Director, Pennsylvania Society of Health-System Pharmacists

Genevieve Levans, R.Ph., Hospital of the University of Pennsylvania

Derek Smoody, Regional Medical Affairs Manager, Braeburn Pharmaceuticals

Charlotte Harris, Pharmacy Intern, Duquesne University Dave Wrzesniewski, Regional Manager, Pharmacy Operations, The GIANT Company

Susan DelMonico, R.Ph., JD

Edward Foote, Pharm.D., FCCP, BCPS, Dean, Philadelphia College of Pharmacy at the University of Sciences

Sarah Everingham, MJ, CCEP, CPhT, Cardinal Health Joshua Finger, Pharm.D., Enclara Pharmacia Geoffrey Christ, Senior Pharmacy Compliance Manager,

Chewv Jacquelyn Sassaman, Pentec Health Megan Ammon, PharmD, BCMTMS, Clinical Program

Coordinator at Weis Markets Christopher Miller, PharmD, Giant Eagle

Joseph Milward, Senior Manager, Pharmacy Quality and Accreditation, PANTHERx Rare Pharmacy

Nicole Fidler, Associate, Malady & Wooten

Misha Patel, M.D., Curriculum Education Assistant, Geisinger Commonwealth School of Medicine

Jim Reed, Health Outcomes Supervisor/Strategic Partnerships Leader, Walgreens

Laura Romeo, Pharmacist-in-Charge at ConnectiveRx, Careform Pharmacy

State Board of Pharmacy December 19, 2023

ALSO PRESENT: (cont.)

Jennifer Smeltz, Republican Executive Director, Senate Consumer Protection & Professional Timothy Black, R.Ph., Pharmacy Inspector, Bureau of

Timothy Black, R.Ph., Pharmacy Inspector, Bureau of Enforcement and Investigation, Department of State Steven Zahn, Pharmacy Inspector, Bureau of

Enforcement and Investigation, Department of State Stephanie Monteiro, Specialist, Engineering at Merck & Company

Patrick Lavella, R.Ph., President, Pennsylvania Pharmacist Association

Rhonda Thomas, PharmD, MBA, BSPS, BCSCP, Director of Pharmacy, Lehigh Valley Health Network

Raymond Vellky, PharmD, Delta 9 PA by Keystone Integrated Care

Valerie Pentland, PharmD, ConnectiveRx Andv

Leah Castelnovo, Pharmacy Student at the University of Pittsburgh
Matthew Ford

1

2 State Board of Pharmacy

3 December 19, 2023

* * *

5 | [Pursuant to Section 708(a)(5) of the Sunshine Act,

6 at 9:00 a.m., the Board entered into Executive

7 | Session with Ariel E. O'Malley, Esquire, Board

8 Counsel, for the purpose of conducting quasi-judicial

9 deliberations and to receive the advice of Board

10 Counsel. The Board returned to open session at

11 10:30 a.m.]

4

12

The regularly scheduled meeting of the State

14 Board of Pharmacy was held on Tuesday, December 19,

15 2023. Theresa M. Talbott, R.Ph., Chairperson, called

16 the meeting to order at 10:31 a.m.

17

18 Introduction of the Board Members/Audience

19 [Theresa M. Talbott, R.Ph., Chairperson, requested

20 | the introduction of Board members and the audience.]

21

22 [Theresa M. Talbott, R.Ph., Chairperson, noted that

23 the meeting was being recorded, and those who

24 | continued to participate were giving their consent to

25 be recorded.]

```
6
1
2
   Evacuation Announcement
3
   [Melanie Zimmerman, R.Ph., Board Administrator,
4
   reviewed the emergency evacuation procedures for 2525
5
   North 7th Street.
                               * * *
6
7
   Approval of the Agenda
8
   CHAIRPERSON TALBOTT:
9
                 I will entertain a motion to accept the
10
                 agenda as presented.
11
   MR. ESTERBROOK:
                 So moved.
12
13
   MS. GETZEY HART:
14
                 Second.
15
   CHAIRPERSON TALBOTT:
16
                 Any discussion? Call the vote.
17
18
                 Hart, aye; Esterbrook, aye; Ritchie, aye;
19
                 Claggett, aye; Talbott, aye; Roussel,
20
                 aye; Slagle, aye.
21
   [The motion carried unanimously.]
22
23
   Approval of Minutes
24
   CHAIRPERSON TALBOTT:
25
                 At item 4, we have the minutes from the
```

```
1
                 November 7 meeting. Did anybody have any
2
                 concerns about the minutes?
3
   MR. ESTERBROOK:
4
                 Motion to accept the minutes.
5
   MS. GETZEY HART:
                 Second.
6
7
   CHAIRPERSON TALBOTT:
8
                 Any further discussion? Call the vote.
9
10
                 Hart, aye; Esterbrook, aye; Ritchie, aye;
11
                 Claggett, aye; Talbott, aye; Roussel,
12
                 aye; Slagle, aye.
13
   [The motion carried unanimously.]
14
15
   Report of Board Prosecution
16
   [Glenn P. Masser, Esquire, Board Prosecutor,
17
   presented the Consent Agreement for Case Nos. 22-54-
18
   016048 & 22-54-016588.]
                              * * *
19
20
   [Glenn Masser experienced technical difficulties at
21
   10:37 a.m.]
22
                              * * *
23
   [Theresa M. Talbott, R.Ph., Chairperson, exited the
24
   meeting at 10:37 a.m. for recusal purposes.]
25
```

```
VICE CHAIR ROUSSEL ASSUMED THE CHAIR
1
                              * * *
2
3
   [Ashley P. Murphy, Esquire, Board Prosecutor,
4
   presented the Consent Agreement for Case Nos. 21-54-
5
   018991 & 22-54-010724.1
                              * * *
6
7
   [Theresa M. Talbott, R.Ph., Chairperson, reentered
   the meeting at 10:38 a.m.]
10
            CHAIRPERSON TALBOTT RESUMED THE CHAIR
                              * * *
11
12
   [Glenn P. Masser, Esquire, Board Prosecutor,
13
   continued the presentation for the Consent Agreements
14
   at Case Nos. 22-54-016048 \& 22-54-016588, Case No.
15
   23-54-011156, and Case Nos. 23-54-010874 & 23-54-
16
   014562.1
17
18
   [Eric Esterbrook, R.Ph., Secretary, exited the
19
   meeting at 10:43 a.m. for recusal purposes.]
                              * * *
20
21
   [Glenn P. Masser, Esquire, Board Prosecutor,
22
   presented the Consent Agreement for Case Nos. 22-54-
23
   015271 & 22-54-015272.]
24
25
   [Eric Esterbrook, R.Ph., Secretary, reentered the
```

```
9
1
   meeting at 10:44 a.m.]
                              * * *
2
3
   [Nathan C. Giunta, Esquire, Board Prosecution
4
   Liaison, presented the Consent Agreement for Case No.
5
   23-54-010283.1
                              * * *
6
7
   [Janet Getzey Hart, R.Ph., exited the meeting at
   10:47 a.m. for recusal purposes.]
9
10
   [Nathan C. Giunta, Esquire, Board Prosecution
11
   Liaison, presented the Consent Agreement for
   Case No. 23-54-015426.]
12
13
                              * * *
14
   [Janet Getzey Hart, R.Ph., reentered the meeting at
15
   10:49 a.m.]
16
17
   [Ray J. Michalowski, Esquire, Senior Board
18
   Prosecutor, presented the VRP Agreements for Case No.
   23-54-013663 and Case No. 23-54-013664.1
19
                              * * *
20
21
   Appointment - Introduction
22
   [Michael McDonald, Policy Director, Department of
23
   State, introduced himself and provided a brief
24
   history of his personal and professional background.
25
   He informed everyone that the policy office works
```

with all of the program areas, including all of the licensing boards and commissions, to help set policy.

Mr. McDonald noted working closely with Board Counsel; to draft or review proposed regulations. He noted the policy office researches policies in other jurisdictions that may impact Pennsylvanians or licensees. He stated the policy office is a resource for new ideas and offered to assist with implementing policies and new regulations.

Mr. McDonald also mentioned working closely with Acting Commissioner Claggett and Deputy Policy Director Andrew LaFratte, who would also be available to answer any questions or concerns.

Mr. McDonald thanked Board members for their service to the licensees and citizens of the Commonwealth of Pennsylvania.

Chair Talbott informed Mr. McDonald that the regulatory process in Pennsylvania is horrible, where some regulations have taken seven years to be promulgated. She offered the Board's assistance to help with anything that could be done with the antiquated regulatory process.

Mr. McDonald was aware of the slow regulatory process, noting the Policy Office is always looking at ways to streamline the processes in place for

- 1 internal review and looking at ways to move things
 2 along quickly.]
- 3 | ***
- 4 | Appointment Physicians' Health Program
- 5 [Tiffany Booher, MA, LPC, CAADC, CIP, CCSM, Director,
- 6 | Peer Assistance Monitoring Programs; Program
- 7 | Director, Physicians' Health Program, Pennsylvania
- 8 Medical Society, presented to the Board to discuss
- 9 | the Physicians' Health Program.
- 10 Raymond Truex Jr., MD, FACS, FAANS, Medical
- 11 Director, Physicians' Health Program, The Foundation
- 12 of the Pennsylvania Medical Society, and Heather A.
- 13 Wilson, MSW, CFRE, CAE, Executive Director of The
- 14 Foundation of the Pennsylvania Medical Society,
- 15 Deputy Executive Vice President of the Pennsylvania
- 16 Medical Society, introduced themselves.
- 17 Ms. Booher addressed the history of the
- 18 | Physicians' Health Program. She noted their program
- 19 to be one of the oldest and well-established
- 20 physicians' health programs in the nation and being a
- 21 member of the Federation of State Physician Health
- 22 | Programs.
- 23 Ms. Booher noted the program started as a hotline
- 24 | in the 1970s by volunteer physicians willing to take
- 25 calls from physicians who had substance abuse or

mental health problems and needed support. She stated it developed into an official program in 1986 and then recognized by the Board of Medicine in 1989 to provide peer assistance in the Commonwealth.

Ms. Booher noted being a 501(c)(3) charitable affiliate of the Pennsylvania Medical Society and being funded by charitable donations from hospital systems, the public, and other physicians and healthcare professionals interested in supporting their peers. She mentioned also being funded by the monthly monitoring fees from participants and charitable donations from associations.

Ms. Booher addressed foundation core values regarding the operation of the program and staff with the highlight on quality and confidentiality, noting the Physicians' Health Program (PHP) does not release any information without a release of information from their participants.

Ms. Booher noted that the mission of PHP is to work with professionals who have substance abuse disorders, mental health disorders, and other behavioral concerns that may be interfering with them being able to practice. She stated PHP provides case management services and refers individuals for evaluation and treatment with a trusted independent

provider in the treatment and evaluation of healthcare professionals.

Ms. Booher noted PHP provides monitoring and advocacy services, including custody hearings. She provided a list of people PHP serves and highlighted that they have students from all professions. She noted building relationships with pharmacy schools and being grateful for the outreach of leadership. She reported having a couple of referrals from some of the pharmacy schools and noted the importance of continuing that collaborative relationship as they move forward.

Ms. Booher stated the Physicians' Health Program uses a success first model to get individuals the treatment they need at the highest level of care to achieve the best outcomes possible. She mentioned that people are more likely to be referred to inpatient treatment for the initial evaluation so all avenues of what is best for them could be addressed. She noted they work with participants regarding the evaluation expense.

Ms. Booher addressed the importance of early detection and educating the public to hopefully get individuals early on in the process before they ruin their careers and potentially endanger the public.

She reported that individuals are more successful throughout the process than if they send them for outpatient evaluation. She emphasized that thorough assessment is the gateway to really helping someone be successful in recovery.

Ms. Booher noted having an abstinence-based program model but allowing people on medication for opioid use disorder (MOUD) or other medications to assist them in their recovery and that they do not prohibit anybody from entering into their program. She noted those individual may require neurocognitive assessment to make sure that they are not impaired as they move back to practice.

Ms. Booher noted having an initial five-year long-term monitoring program and a shorter period of time for individuals who are in a mental health situation without the co-occurring substance use disorder. She also addressed other long-term monitoring agreements, including a 20-year agreement in monitoring called a lifetime agreement with no end date that is free of charge.

Ms. Booher explained that the agreements are voluntary, where after completing their Professional Health Monitoring Program (PHMP) responsibilities, they can leave with no penalties or consequences as

long as they are in good compliance with their monitoring agreement.

Ms. Booher addressed the collection of documentation, including psychiatric reports, medications, drug testing results, CME, and coaching experience. She noted PHP pairs each individual in the program with a peer monitor who provides a quarterly report, along with reports collected from the workplace monitor quarterly. She mentioned also having a liaison so an individual at their workplace could stop them from practicing if necessary.

Ms. Booher provided statistics from 2022 and the current caseload as well. She offered to provide any specific statistics the Board would like to see each year. She reported currently monitoring 39 pharmacists out of 304 cases.

Ms. Booher noted being in business for over 35 years and helping over 5000 cases. She reported receiving 148 referrals in 2022 and signing 70 monitoring agreements last year with an average of 333 active participants each month. She mentioned having a very large staff to handle those cases.

Ms. Booher addressed participants by profession, noting the majority are physicians with one pharmacy student in active monitoring and the rest in the

pending evaluation phase but have not moved through the process.

Ms. Booher provided referrals by source, noting PHMP referrals were at 63% last year and 70% this year and reported the majority of individuals are coming from licensing boards and the PHMP. She also reported 12% are self-referrals, 8% are from schools, and 6% from hospital systems. She mentioned a small portion of individuals are also from out-of-state PHPs because they offer an interstate monitoring agreement. She also noted receiving referrals from treatment providers and residency programs. She reported over 100 agreement signings in 2023 and an upshoot with pharmacists in October.

Ms. Booher discussed the types of agreements offered, including a general substance use disorder agreement. She noted offering a non-advocacy agreement for individuals who are financially unable to follow the recommendations of typical inpatient treatment and wants to go for intensive outpatient treatment or partial hospitalization, which lasts anywhere from 3 to 12 months.

Ms. Booher further explained that they would not provide advocacy to those individuals until they transition them into an advocacy agreement and would

- 1 | not allow them to work during that period of time.
- 2 | And it kind of breaks down that financial piece that
- 3 sometimes inhibits people from moving forward in
- 4 their recovery or entering into monitoring.
- 5 Ms. Booher addressed re-signing, where
- 6 | individuals relapsed while in monitoring, left and
- 7 came back, or were done with monitoring and relapsed.
- 8 | She also addressed long-term monitoring agreements,
- 9 interstate agreements, and psychiatric agreements.
- 10 Ms. Booher noted PHP offers a rule-out agreement
- 11 for one-year monitoring called a sobriety challenge,
- 12 where there is deep concern during the evaluation
- 13 process, but they do not meet diagnostic criteria for
- 14 a diagnosis. She explained that individuals would be
- 15 drug tested and have workplace monitoring but not all
- 16 of the other peer monitoring.
- 17 Ms. Booher mentioned that students are frequently
- 18 in the rule-out agreement because the evaluator
- 19 believed they are not being completely honest. She
- 20 | noted that individuals are offered a one-year
- 21 monitoring agreement to give them some accountability
- 22 and to make sure nothing is going on. She explained
- 23 that the individuals are applying for their license
- 24 because they do not have a diagnosis and would not be
- 25 answering yes to the questions that would trigger

PHMP participation.

Ms. Booher reported one individual signed a lifetime agreement in 2023. She also reported that an occupational agreement was signed, which is for individuals who have a behavioral issue at work but may not meet diagnostic criteria for a mental health condition. She noted PHP works collaboratively with the employer to set up an agreement that supports ongoing monitoring of their behavior.

Ms. Booher stated their medical directors and case managers meet via Zoom with the participant during the agreement signing to walk them through the entire monitoring agreement.

Ms. Booher emphasized that PHP staff really cares about the success of participants and their best interest, noting participants are required to call and check in monthly and referred to resources to help with any challenges. She mentioned that they spend a lot of time working with their advisory committee and staff twice a week to discuss cases to make sure every decision is fair and equitable and support the participant's recovery and best interest.

Ms. Booher stated PHP utilizes best practices and an evidence-based model and that they change their policies and procedures regularly. She commented

that monitoring saves lives and offered their
assistance with any questions or concerns.

Ms. Booher informed Board members that John Kriak is officially on the advisory committee as a pharmacist member and is committed to supporting his peers. She noted Dr. Kriak is already engaged as one of their peer monitors.

Ms. Booher asked whether Board members were interested in specific statistics and offered to provide that information.

Chair Talbott informed Ms. Booher that the Board would get back with her after further discussion at the next meeting.]

Report of Board Counsel - Legislative Report

[Ariel E. O'Malley, Esquire, Board Counsel, informed

Board members that Senate Bill 910 passed and was

signed on December 15, which increases the ability to

expunge offenses and extends it to what is on the

schedule of civil penalties.

Ms. O'Malley noted House Bill 1661, which addresses the inappropriate use of xylazine, passed the House on October 4, 2023, went to the Senate, and was then referred to the Agricultural and Rural Affairs Committee, and has been with their

Appropriations Committee since November 15, 2023.

Ms. O'Malley referred to Senate Bill 959 regarding scheduling of controlled substances, where the Secretary would follow the federal stance. She explained that it essentially sets up a procedure where the Secretary would get the schedules, which would automatically be published in the Legislative Reference Bureau, and the sets up like an appeals procedure for scheduling under the Drug Act. She further explained that a notice would get published in the Legislative Reference Bureau and provides for an opportunity to file a substantial written objection and participation in the hearing.

Ms. O'Malley commented that this process is supposed to make it easier for the scheduling of substances and to follow the federal level. She noted the bill was introduced on October 16, 2023, and was referred to the Judiciary Committee.

Ms. O'Malley noted House Bill 1882 was introduced on November 6, 2023, and passed the House on December 13, 2023, as a result of Operation Nightingale, which would give the Board the ability to rescind a license, registration, or permit where there is probable cause that the license was obtained based on false or fraudulent documentation.]

21 1 2 Report of Board Counsel - Regulatory Report 3 [Ariel E. O'Malley, Esquire, Board Counsel, informed 4 Board members that there had not been much movement 5 with the regulations. She will be meeting with Marc Farrell and provide an updated Regulatory Report at 6 7 the next meeting. Ms. O'Malley informed Board members that the pharmacy tech regulation was approved by the Office 10 of General Counsel (OGC) and then sent to the Office 11 of Attorney General (OAG) as of December 15, 2023. 12 She hoped to have that published as proposed at the 13 beginning of the year and published soon thereafter 14 as final.] 15 16 Report of Board Prosecution (cont.) 17 CHAIRPERSON TALBOTT: 18 The Board of Pharmacy met in Executive Session to discuss and review consent 19 20 orders and other legal documents. 21 Are there any motions regarding 22 these discussions? 23 MR. ESTERBROOK: 24 I move to accept the Consent Agreement 25 for Case Nos. 22-54-016048 & 22-54-

22 016588. 1 2 CHAIRPERSON TALBOTT: 3 We have a motion. Do we have a second? 4 MS. GETZEY HART: 5 Second. 6 CHAIRPERSON TALBOTT: 7 Any discussion? Call the vote. 9 Hart, aye; Esterbrook, aye; Ritchie, aye; 10 Claggett, aye; Talbott, aye; Roussel, 11 aye; Slagle, aye. 12 [The motion carried unanimously. The Respondents are 13 Broad & Grange Pharmacy, Inc., and Roseland N. Ntege, 14 R.Ph.] 15 16 MR. ESTERBROOK: 17 I move to accept the Consent Agreement for Case No. 23-54-011156. 18 CHAIRPERSON TALBOTT: 19 20 Do we have a second? 21 MS. GETZEY HART: 22 Second. 23 CHAIRPERSON TALBOTT: 24 Any discussion? Call the vote. 25

```
23
1
                 Hart, aye; Esterbrook, aye; Ritchie, aye;
2
                 Claggett, aye; Talbott, aye; Roussel,
3
                 aye; Slagle, aye.
4
   [The motion carried unanimously. The Respondent's
5
   name is Edgar R. Gonzalez.]
                              * * *
6
7
   MR. ESTERBROOK:
                 I move to accept the Consent Agreement
                 for Case Nos. 23-54-010874 \& 23-54-
9
10
                 014562.
11
   MS. GETZEY HART:
                 Second.
12
13
   CHAIRPERSON TALBOTT:
14
                 Any discussion? Call the vote.
15
16
                 Hart, aye; Esterbrook, aye; Ritchie, aye;
                 Claggett, aye; Talbott, aye; Roussel,
17
18
                 aye; Slagle, aye.
19
   [The motion carried unanimously. The Respondents are
20
   Boothwyn Pharmacy, LLC, and Wayne Charles Sartorio,
21
   R.Ph.]
22
23
   MR. RITCHIE:
24
                 I move to accept the Consent Agreement
25
                 for Case Nos. 22-54-015271 \& 22-54-
```

24 015272. 1 2 DR. ROUSSEL: 3 Second. 4 CHAIRPERSON TALBOTT: 5 Any discussion? Call the vote. 6 7 Hart, aye; Esterbrook, recuse; Ritchie, 8 aye; Claggett, aye; Talbott, aye; 9 Roussel, aye; Slagle, aye. 10 [The motion carried. Eric Esterbrook recused himself 11 from deliberations and voting on the motion. The 12 Respondents' names are Global Pharmacy, Inc., and 13 Zachary John Schmehl. 14 15 MR. ESTERBROOK: 16 I move to accept the Consent Agreement for Case Nos. 21-54-018991 & 22-54-17 18 010724. MS. GETZEY HART: 19 20 Second. 21 CHAIRPERSON TALBOTT: 22 Any discussion? Call the vote. 23 24 Hart, aye; Esterbrook, aye; Ritchie, aye; 25 Claggett, aye; Talbott, recuse; Roussel,

```
25
1
                 aye; Slagle, aye.
2
   [The motion carried. Theresa Talbott recused herself
3
   from deliberations and voting on the motion.
4
   Respondents' names are CVS Pharmacy 1920 & Eric A.
5
   Smith, R.Ph.
                              * * *
6
7
   MR. ESTERBROOK:
8
                 I move to accept the Consent Agreement
9
                 for Case No. 23-54-010283.
10
   MS. GETZEY HART:
11
                 Second.
   CHAIRPERSON TALBOTT:
12
13
                 Any discussion? Call the vote.
14
15
                 Hart, aye; Esterbrook, aye; Ritchie, aye;
16
                 Claggett, aye; Talbott, aye; Roussel,
17
                 aye; Slagle, aye.
18
   [The motion carried unanimously. The Respondent's
19
   name is Michael Robert Benzon, R.Ph.]
                              * * *
20
21
   MR. ESTERBROOK:
22
                 I move to accept the Consent Agreement
23
                 for Case No. 23-54-015426.
24
   MR. RITCHIE:
25
                 Second.
```

26 CHAIRPERSON TALBOTT: 1 2 Any discussion? Call the vote. 3 4 Hart, recuse; Esterbrook, aye; Ritchie, 5 aye; Claggett, aye; Talbott, aye; 6 Roussel, aye; Slagle, aye. 7 [The motion carried. Janet Getzey Hart recused herself from deliberations and voting on the motion. The Respondent's name is Haylie Rae Fefolt, R.Ph. * * * 10 11 MR. ESTERBROOK: 12 I move to accept the Consent Agreement 13 for VRP Case No. 23-54-013663. 14 MS. GETZEY HART: 15 Second. 16 CHAIRPERSON TALBOTT: 17 Any discussion? Call the vote. 18 19 Hart, aye; Esterbrook, aye; Ritchie, aye; 20 Claggett, aye; Talbott, aye; Roussel, aye; Slagle, aye. 21 22 [The motion carried unanimously.] 23 24 MR. ESTERBROOK: 25 I move to accept the Consent Agreement

27 for VRP Case No. 23-54-013664. 1 2 MS. GETZEY HART: 3 Second. CHAIRPERSON TALBOTT: 4 5 Any discussion? Call the vote. 6 7 Hart, aye; Esterbrook, aye; Ritchie, aye; 8 Claggett, aye; Talbott, aye; Roussel, 9 aye; Slagle, aye. 10 [The motion carried unanimously.] 11 12 Report of Board Counsel - Matters for Deliberation 13 MR. ESTERBROOK: 14 For Case No. 23-54-009558, I move that 15 Board Counsel; be directed to prepare an 16 Adjudication and Order consistent with our discussion in Executive Session. 17 18 MS. GETZEY HART: 19 Second. CHAIRPERSON TALBOTT: 20 21 Any discussion? Call the vote. 22 23 Hart, aye; Esterbrook, aye; Ritchie, aye; 24 Claggett, aye; Talbott, aye; Roussel, 25 aye; Slagle, aye.

```
28
   [The motion carried unanimously.]
1
2
3
   MR. ESTERBROOK:
 4
                 In the case of Thomas Fortunato, Case No.
5
                 23-54-011152, I move that Board Counsel;
                 be directed to prepare an Adjudication
 6
7
                 and Order consistent with our discussion
                 in Executive Session.
8
9
   MS. GETZEY HART:
10
                 Second.
11
   CHAIRPERSON TALBOTT:
12
                 Any discussion? Call the vote.
13
14
                 Hart, aye; Esterbrook, aye; Ritchie, aye;
15
                 Claggett, aye; Talbott, aye; Roussel,
16
                 aye; Slagle, aye.
17
   [The motion carried unanimously.]
                              * * *
18
19
   MS. O'MALLEY:
20
                 In accordance with discussions in
21
                 Executive Session, I believe the Board
22
                 would entertain a motion to grant the
23
                 Commonwealth's Motion to Withdraw the
24
                 Citation.
25
   MR. ESTERBROOK:
```

29 So moved. 1 2 MS. GETZEY HART: 3 Second. CHAIRPERSON TALBOTT: 4 5 Any discussion? Call the vote. 6 7 Hart, aye; Esterbrook, aye; Ritchie, aye; 8 Claggett, aye; Talbott, aye; Roussel, 9 aye; Slagle, aye. 10 [The motion carried unanimously.] * * * 11 12 13 Report of Board Counsel - Proposed Adjudication and 14 Order 15 MR. ESTERBROOK: 16 I move that the Board adopt the Hearing 17 Examiner's Proposed Adjudication and 18 Order in the Case of Nola Mini Market, 19 LLC, Case No. 23-54-002214, and direct 20 Board Counsel; to prepare the Board's 21 Final Order. 22 MS. GETZEY HART: 23 Second. 24 CHAIRPERSON TALBOTT:

Any discussion? Call the vote.

30 1 2 Hart, aye; Esterbrook, aye; Ritchie, aye; 3 Claggett, aye; Talbott, aye; Roussel, 4 aye; Slagle, aye. 5 [The motion carried unanimously.] * * * 6 7 Report of Board Counsel - Draft Adjudications and 8 Orders 9 MR. ESTERBROOK: 10 I move that the Board adopt the Adjudication and Order as presented by 11 Board Counsel; in the case of 12 13 Anazaohealth Corporation, Case No. 21-54-14 014780, and direct Board Counsel; to 15 prepare the Board's Final Order. MS. GETZEY HART: 16 17 Second. 18 CHAIRPERSON TALBOTT: 19 Any discussion? Call the vote. 20 21 Hart, aye; Esterbrook, aye; Ritchie, aye; 22 Claggett, aye; Talbott, aye; Roussel, 23 aye; Slagle, aye. 24 [The motion carried unanimously.] * * * 25

```
31
   MR. ESTERBROOK:
1
2
                 I move that the Board adopt the
3
                 Adjudication and Order as presented by
 4
                 Board Counsel; in the case of Derek
 5
                 Smoody, Case No. 23-54-004337, and direct
 6
                 Board Counsel; to prepare the Board's
7
                 Final Order.
8
   MS. GETZEY HART:
9
                 Second.
10
   CHAIRPERSON TALBOTT:
11
                 Any discussion? Call the vote.
12
13
                 Hart, aye; Esterbrook, aye; Ritchie, aye;
14
                 Claggett, aye; Talbott, aye; Roussel,
15
                 aye; Slagle, aye.
16
   [The motion carried unanimously.]
                              * * *
17
18
   MR. ESTERBROOK:
19
                 I move that the Board adopt the
20
                 Adjudication and Order as presented by
21
                 Board Counsel; in the case of Brandon
                 Pope, Case No. 22-54-018692, and direct
22
23
                 Board Counsel; to prepare the Board's
24
                 Final Order.
   MS. GETZEY HART:
25
```

32 Second. 1 2 CHAIRPERSON TALBOTT: 3 Any discussion? Call the vote. 4 5 Hart, aye; Esterbrook, aye; Ritchie, aye; 6 Claggett, aye; Talbott, aye; Roussel, 7 aye; Slagle, aye. 8 [The motion carried unanimously.] 9 10 Report of Board Chairperson - Election of Officers 11 [Theresa M. Talbott, R.Ph., Chairperson, informed 12 everyone that her second term will end in May of 2024 13 and this was her final Board meeting as Chair. She stated it had been a pleasure but looked forward to 14 15 passing off the gavel.] CHAIRPERSON TALBOTT: 16 Do we have a nomination for the 17 18 Chairperson? 19 MR. ESTERBROOK: 20 I nominate Christine Roussel. 21 CHAIRPERSON TALBOTT: 22 Do we have a second? 23 MS. GETZEY HART: 24 Second.

25

CHAIRPERSON TALBOTT:

33 1 Are there any other nomination? 2 DR. ROUSSEL: 3 We can move to close nominations. 4 CHAIRPERSON TALBOTT: 5 Call the vote for Christine Roussel being 6 elected Chairperson. 7 Hart, aye; Esterbrook, aye; Ritchie, aye; 9 Claggett, aye; Talbott, aye; Roussel, 10 aye; Slagle, aye. [The motion carried unanimously.] 11 12 13 CHAIRPERSON TALBOTT: 14 Do we have a nomination for Vice Chair? 15 DR. ROUSSEL: 16 I would like to make a motion to nominate Eric Esterbrook for Vice Chair. 17 18 CHAIRPERSON TALBOTT: Do we have a second? 19 20 MS. GETZEY HART: 21 Second. 22 CHAIRPERSON TALBOTT: 23 Do we have any other nominations? Ιf 24 not, I will entertain a motion to close 25 nominations.

34 MS. GETZEY HART: 1 2 Close nominations. 3 CHAIRPERSON TALBOTT: 4 We will have a vote now for Eric to be 5 Vice Chair. 6 7 Hart, aye; Esterbrook, aye; Ritchie, aye; 8 Claggett, aye; Talbott, aye; Roussel, 9 aye; Slagle, aye. 10 [The motion carried unanimously.] 11 CHAIRPERSON TALBOTT: 12 13 Do we have a nomination for Secretary? 14 MR. ESTERBROOK: 15 I make a motion to nominate Janet Hart. 16 CHAIRPERSON TALBOTT: 17 Do we have a second? 18 MR. RITCHIE: Second. 19 20 CHAIRPERSON TALBOTT: 21 Are there any other nominations for the 22 esteemed position of Secretary? 23 MR. ESTERBROOK: 24 Motion to close nominations. 25 CHAIRPERSON TALBOTT:

35 1 Call the vote. 2 3 Hart, aye; Esterbrook, aye; Ritchie, aye; 4 Claggett, aye; Talbott, aye; Roussel, 5 aye; Slagle, aye. 6 [The motion carried unanimously.] 7 * * * 8 Report of Board Chairperson - Selection of Committee 9 Members 10 [Theresa M. Talbott, R.Ph., Chairperson, noted Mr. Ritchie as the Chair of the Probable Cause Screening 11 12 Committee and Ms. Hart as the alternate; Dr. Roussel, 13 Mr. Slagle, Mr. Esterbrook, and Ms. Hart as the 14 alternate for the Pharmacy Application Review 15 Committee; herself as the Cardiopulmonary 16 Resuscitation (CPR) Injectable Training Program 17 Committee member; Ms. Hart as the Act 41 Committee 18 member; Dr. Roussel as the Medical Marijuana Advisory 19 Board member; Mr. Esterbrook, Dr. Roussel, and 20 herself as the Regulation Committee members; and Ms. 21 Hart, Mr. Ritchie, and Mr. Slagle as the Pharmacist 22 Intern Application Review Committee members.] 23 CHAIRPERSON TALBOTT: 24 I would entertain a motion to accept all

those committee assignments.

```
1
   MR. ESTERBROOK:
2
                So moved.
3
   CHAIRPERSON TALBOTT:
 4
                Do we have a second?
5
   MS. GETZEY HART:
                Second.
6
7
   CHAIRPERSON TALBOTT:
8
                Any further discussion? Call the vote.
9
10
                Hart, aye; Esterbrook, aye; Ritchie, aye;
11
                Claggett, aye; Talbott, aye; Roussel,
12
                aye; Slagle, aye.
13
   [The motion carried unanimously.]
14
15
   Report of Acting Commissioner
16
   [Arion R. Claggett, Acting Commissioner, Bureau of
17
   Professional and Occupational Affairs, informed Board
18
   members of recent changes to the Criminal History
19
   Records Check in the Pennsylvania Licensing System
20
   (PALS). He explained that applicants were previously
21
   allowed to request a Criminal History Records Check
22
   through PALS or obtain and upload their own Criminal
23
   History Records Check, but issues were detected with
24
   the connection between the state police and how PALS
25
   received the Criminal History Records Check.
```

```
1
        Acting Commissioner Claggett stated applicants
2
   are now only allowed to upload their own Criminal
3
   History Records Check that they obtained themselves
4
   and are no longer allowed to request a Criminal
5
   History Records Check through PALS.]
                              * * *
6
7
   Report of Board Administrator - No Report
8
9
   Discussion Items - Proposed 2025 Meeting Dates
10
   [Theresa M. Talbott, R.Ph., Chairperson, noted the
11
   proposed 2025 meeting dates are January 21, March 18,
12
   April 29, June 17, July 29, August 26, October 7, and
13
   December 2.1
14
   CHAIRPERSON TALBOTT:
15
                Do we have a motion to accept those
16
                dates?
17
   MR. ESTERBROOK:
18
                 I make a motion to accept those dates as
19
                proposed.
20
   MS. GETZEY HART:
21
                Second.
22
   CHAIRPERSON TALBOTT:
23
                Call the vote.
24
25
                Hart, aye; Esterbrook, aye; Ritchie, aye;
```

```
38
1
                Claggett, aye; Talbott, aye; Roussel,
2
                 aye; Slagle, aye.
3
   [The motion carried unanimously.]
 4
5
   Discussion Items - Selection of PA MPJE Test
     Ouestion Writer
6
7
   [Theresa M. Talbott, R.Ph., Chairperson, asked for
   nominations for the Pennsylvania Multistate Pharmacy
   Jurisprudence Examination (MPJE) test question
10
   writer.
11
   CHAIRPERSON TALBOTT:
12
                Do we have any nominations?
13
   MR. ESTERBROOK:
14
                 I make a motion to appoint Richard Smiga
15
                 as the MPJE test writer.
   MS. GETZEY HART:
16
17
                Second.
18
   CHAIRPERSON TALBOTT:
19
                Any discussion? Call the vote.
20
21
                Hart, aye; Esterbrook, aye; Ritchie, aye;
22
                Claggett, aye; Talbott, aye; Roussel,
23
                aye; Slagle, aye.
24
   [The motion carried unanimously.]
25
```

1 | FYI Items - District II Well-being Index for November

- 2 2023
- 3 | [Theresa M. Talbott, R.Ph., Chairperson, referred to
- 4 | the District II Well-Being Index for November, noting
- 5 Pennsylvania remained relatively stable.]
- ***
- 7 Old Business Newsletter Articles
- 8 | [Theresa M. Talbott, R.Ph., Chairperson, stated the
- 9 Board had a prior discussion concerning a newsletter
- 10 and would be compiling various items for the next
- 11 | Board meeting on February 6.]
- 12
- 13 Public Comment
- 14 | [Ray J. Michalowski, Esquire, Senior Board
- 15 Prosecutor, referred to a recent inspection and a
- 16 question that arose as to whether it is still the
- 17 | position of the Board that adding commercial
- 18 | flavorings in a pharmacy was not to be considered
- 19 | compounding.]
- 20 CHAIRPERSON TALBOTT:
- 21 We should have it as an official motion
- that we do not consider that.
- 23 MS. GETZEY HART:
- I make a motion that the Board does not
- 25 consider adding flavor into a

```
40
1
                prescription to be compounding under USP
2
                Standards.
3
   CHAIRPERSON TALBOTT:
 4
                Do we have a second?
5
   MR. ESTERBROOK:
                Second.
6
7
   CHAIRPERSON TALBOTT:
8
                Any other discussion?
9
   [Dr. Roussel mentioned being the Pennsylvania
10
   representative for the Food and Drug Administration
11
   Intergovernmental Working Meeting on Drug
12
   Compounding. She mentioned Virginia also does not
13
   consider conventionally manufactured products to
14
   constitute compounding.]
15
   CHAIRPERSON TALBOTT:
16
                Any other discussion? Call the vote.
17
18
                Hart, aye; Esterbrook, aye; Ritchie, aye;
19
                Claggett, aye; Talbott, aye; Roussel,
20
                aye; Slagle, aye.
21
   [The motion carried unanimously.]
22
23
   Public Comment
24
   [Geoffrey Christ, Senior Pharmacy Compliance Manager,
25
   Chewy, offered to help with the MPJE question writing
```

1 and was told to send an email and his resume to Ms. 2 Zimmerman.

Dr. Roussel addressed her attendance at the FDA Intergovernmental Work Meeting on Compounding November 7-8. She mentioned that slides from the FDA are available for free on their website. She noted they presented different regulations, both draft and required. She also noted they reviewed the United States Pharmacopeia (USP) and spent a lot of time on unsanitary conditions and reviewing the difference between 503A and 503B pharmacies and the regulations.

An unidentified SPEAKER 1:22:04 commented that Ohio also has guidelines out regarding compounding and asked whether the Board would consider looking at what is happening in surrounding states because she is getting a lot of questions from pharmacies that are anticipating inspectors to come in and revisit the regulations they are now acknowledging and are requesting some clarification.

Chair Talbott requested the Ohio regulations be sent to Ms. O'Malley for the Board to take a look at those regulations.]

* * *

24 Adjournment

25 [Theresa M. Talbott, R.Ph., Chairperson, wished

```
42
   everyone happy holidays on behalf of the Board.]
1
                               * * *
2
3
   [The Board recessed from 11:54 a.m. until 1:19 p.m.]
4
                               * * *
5
   [A Formal Hearing was held from 1:19 p.m. until
6
   2:59 p.m. in the Matter of the Petition for
7
   Reinstatement of Anthony Albert Grejda, R.Ph., to
8
   Non-suspended, Unrestricted Status, Case No. 23-54-
9
   011183.]
10
11
   [There being no further business, the State Board of
12
   Pharmacy Meeting adjourned at 2:59 p.m.]
13
                               * * *
14
15
16
17
18
19
20
21
22
23
24
25
26
```


 CERTIFICATE

I hereby certify that the foregoing summary minutes of the State Board of Pharmacy meeting, was reduced to writing by me or under my supervision, and that the minutes accurately summarize the substance of the State Board of Pharmacy meeting.

Matthew Ford,

Minute Clerk

Sargent's Court Reporting

Service, Inc.

		44
1 2 3		STATE BOARD OF PHARMACY REFERENCE INDEX
4 5 6		December 19, 2023
6 7 8	TIME	AGENDA
9 10 11	9:00 10:30	Executive Session Return to Open Session
12	10:31	Official Call to Order
13 14	10:31	Introduction of Board Members/Audience
15 16	10:34	Approval of Agenda
17 18	10:35	Approval of Minutes
19 20	10:36	Report of Board Prosecution
21 22 23	10:50	Appointment - Michael McDonald, Policy Director, Department of State
242526	11:00	Appointment - Physicians' Health Program
27 28	11:26	Report of Board Counsel
29 30	11:31	Report of Board Prosecution (cont.)
31 32	11:35	Report of Board Counsel (cont.)
33 34	11:40	Report of Board Chairperson
35 36 37 38 39 40	11:44	Report of Acting Commissioner
	11:46	Discussion Items
	11:48	FYI Items
41 42	11:48	Old Business
43	11:49	Public Comment
45 46 47 48 49 50	11:55 1:19	

		45
	STATE BOARD OF PHARMACY REFERENCE INDEX (cont.) December 19, 2023	
TIME	AGENDA	
1:19 2:59	Formal Hearing - Anthony Albert Grejda, R.Ph.	
2:59	Adjournment	